<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474029</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHSTP-7024</org_study_id>
    <nct_id>NCT03474029</nct_id>
  </id_info>
  <brief_title>Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI</brief_title>
  <acronym>ASTERoiD</acronym>
  <official_title>Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to compare the safety and effectiveness of a novel short 6-week
      regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of
      rifamycin-based treatment (standard of care, control arm) of latent M. tuberculosis infection
      (LTBI).

      This trial is conducted among persons who are at increased risk of progression to
      tuberculosis (TB) and require treatment of LTBI. The study will be conducted in the United
      States, the United Kingdom, and other countries with low to moderate TB incidence (&lt; 100 TB
      cases per 100,000 population) that have treatment of LTBI as their standard of care and offer
      12-16 week rifamycin-based therapy as standard of care.

      The hypothesis of this study is that the safety and effectiveness of the experimental
      treatment (6wP arm) is non-inferior to a comparator arm of 12-16 weeks of rifamycin-based
      treatment of LTBI (control arm).

      Participants are enrolled and randomly assigned to one of the two study arms: experimental
      6wP or control. The comparator (control) arm's treatment regimens include 12 weeks of
      once-weekly isoniazid (INH) and rifapentine (3HP), 12 weeks of daily INH and rifampin (3HR),
      and 16 weeks of daily rifampin (4R). A total of 560 participants per arm (1,120 total) for
      the evaluation of safety and 1,700 participants per arm (3,400 total) for the evaluation of
      effectiveness will be enrolled, given treatment as per randomization assignment, and followed
      for 24 months from the date of enrollment.

      After completion of data collection, statistical analyses will be conducted to compare
      proportions of drug discontinuation due to adverse drug reaction (ADR) and proportions of
      newly diagnosed tuberculosis between 6wP and control arm.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment discontinuation due to adverse drug reaction</measure>
    <time_frame>from the date of enrollment to the date of scheduled completion of assigned treatment</time_frame>
    <description>Safety outcome. Drug discontinuation due to adverse drug reaction (ADR) associated with experimental treatment (6wP) or active comparator treatment (the rifamycin-based 3HP, 3HR, or 4R) . Attribution of an adverse event (AE) to study drugs will be determined by the local site investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Culture-confirmed tuberculosis (TB) in participants 18 years old and older and culture-confirmed or clinical TB in participants less then 18 years old.</measure>
    <time_frame>within 24 months from the date of enrollment</time_frame>
    <description>Effectiveness outcome. Culture-confirmed tuberculosis (TB) in participants 18 years old and older and culture-confirmed or clinical TB in participants less then 18 years old. Diagnosis of culture-confirmed TB will be performed using liquid and/or solid media methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion who complete assigned treatment</measure>
    <time_frame>from date of enrollment until the maximum accepted time for treatment completion as follows: 9 weeks for 6wP treatment, 16 weeks for 3HP, 16 weeks for 3HP, and 21 weeks for 4R</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with drug discontinuation for any reason</measure>
    <time_frame>from date of enrollment until the maximum accepted time for treatment completion as follows: 9 weeks for 6wP treatment, 16 weeks for 3HP, 16 weeks for 3HP, and 21 weeks for 4R</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with any grade 3, 4, or 5 (i.e., death) adverse event associated with study drug</measure>
    <time_frame>from date of enrollment to the date of treatment completion plus 14 days: up to 11 weeks for 6wP treatment, up to 18 weeks for 3HP, up to 18 weeks for 3HP, and up to 23 weeks for 4R.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion who have died for any reason</measure>
    <time_frame>within 24 months from the date of enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with hepatitis and non-hepatotoxic systemic drug reactions</measure>
    <time_frame>from date of enrollment to the date of treatment completion plus 14 days: up to 11 weeks for 6wP treatment, up to 18 weeks for 3HP, up to 18 weeks for 3HP, and up to 23 weeks for 4R.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with culture-confirmed or clinical TB regardless of age</measure>
    <time_frame>within 24 months from the date of enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with TB among those who complete assigned therapy</measure>
    <time_frame>within 24 months from the date of enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (defined as treatment discontinuation due to adverse drug reaction) among participants with human immunodeficiency virus (HIV) infection.</measure>
    <time_frame>from date of enrollment until the maximum accepted time for treatment completion as follows: 9 weeks for 6wP treatment, 16 weeks for 3HP, 16 weeks for 3HP, and 21 weeks for 4R</time_frame>
    <description>Proportion of HIV-infected patients with drug discontinuation due to adverse drug reaction (ADR) associated with experimental treatment (6wP) or active comparator treatment (the rifamycin-based 3HP, 3HR, or 4R) . Attribution of an adverse event (AE) to study drugs will be determined by the local site investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (defined as treatment discontinuation due to adverse drug reaction) among participants &lt; 18 years old.</measure>
    <time_frame>from date of enrollment until the maximum accepted time for treatment completion as follows: 9 weeks for 6wP treatment, 16 weeks for 3HP, 16 weeks for 3HP, and 21 weeks for 4R</time_frame>
    <description>Proportion of participants &lt; 18 years old with drug discontinuation due to adverse drug reaction (ADR) associated with experimental treatment (6wP) or active comparator treatment (the rifamycin-based 3HP, 3HR, or 4R) . Attribution of an adverse event (AE) to study drugs will be determined by the local site investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability (defined as proportion of with drug discontinuation for any reason) among participants with human immunodeficiency virus (HIV) infection.</measure>
    <time_frame>from date of enrollment until the maximum accepted time for treatment completion as follows: 9 weeks for 6wP treatment, 16 weeks for 3HP, 16 weeks for 3HP, and 21 weeks for 4R</time_frame>
    <description>Proportion of HIV-infected patients with drug discontinuation for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability (defined as proportion of with drug discontinuation for any reason) among participants &lt; 18 years old.</measure>
    <time_frame>from date of enrollment until the maximum accepted time for treatment completion as follows: 9 weeks for 6wP treatment, 16 weeks for 3HP, 16 weeks for 3HP, and 21 weeks for 4R</time_frame>
    <description>Proportion of participants &lt; 18 years old with drug discontinuation for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness among participants with human immunodeficiency virus (HIV) infection.</measure>
    <time_frame>within 24 months from the date of enrollment</time_frame>
    <description>Proportion of HIV-infected patients with culture-confirmed tuberculosis (TB) in participants 18 years old and older and culture-confirmed or clinical TB in participants less then 18 years old. Diagnosis of culture-confirmed TB will be performed using liquid and/or solid media methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness among participants &lt; 18 years old.</measure>
    <time_frame>within 24 months from the date of enrollment</time_frame>
    <description>Proportion of participants &lt; 18 years old with culture-confirmed tuberculosis or clinical TB. Diagnosis of culture-confirmed TB will be performed using liquid and/or solid media methods.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportions of drug discontinuation due to adverse drug reactions in experimental (6wP) arm and each treatment regimen in the comparator arm: 3HP, 3HR, 4R</measure>
    <time_frame>from date of enrollment until the maximum accepted time for treatment completion as follows: 9 weeks for 6wP treatment, 16 weeks for 3HP, 16 weeks for 3HP, and 21 weeks for 4R</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportions of treatment discontinuations for any reason in experimental (6wP) arm and each treatment regimen in the comparator arm: 3HP, 3HR, 4R</measure>
    <time_frame>from date of enrollment until the maximum accepted time for treatment completion as follows: 9 weeks for 6wP treatment, 16 weeks for 3HP, 16 weeks for 3HP, and 21 weeks for 4R</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effectiveness of experimental (6wP) arm and each treatment regimen in the comparator arm: 3HP, 3HR, 4R</measure>
    <time_frame>within 24 months from the date of enrollment</time_frame>
    <description>Proportion of participants with culture-confirmed tuberculosis (TB) in participants 18 years old and older and culture-confirmed or clinical TB in participants less then 18 years old. Diagnosis of culture-confirmed TB will be performed using liquid and/or solid media methods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of treatment completion with an alternative regimen after discontinuation of study therapy</measure>
    <time_frame>from the date of enrollment to the date of scheduled completion of assigned treatment (up to 24 month)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion with resistance to rifamycins or isoniazid among persons who develop TB to each regimen in the comparator arm: 3HP, 3HR, 4R.</measure>
    <time_frame>within 24 months from the date of enrollment</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3400</enrollment>
  <condition>Latent Tuberculosis</condition>
  <arm_group>
    <arm_group_label>6 weeks of daily rifapentine (6wP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifapentine daily for 6 weeks: 600 mg of Rifapentine (RPT) given once daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-16 week rifamycin-based regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 12-16 week rifamycin-based regimen available at the participant's site:
&quot;Rifapentine and Isoniazid weekly for 12 weeks&quot; (3HP) or &quot;Rifampin and Isoniazid daily for 12 weeks&quot; (3HR) or &quot;Rifampin daily for 16 weeks&quot; (4R)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifapentine daily for 6 weeks</intervention_name>
    <description>600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).</description>
    <arm_group_label>6 weeks of daily rifapentine (6wP)</arm_group_label>
    <other_name>priftin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifapentine and Isoniazid weekly for 12 weeks</intervention_name>
    <description>Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).*
*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.
RPT 900 mg once-weekly for persons weighing &gt; 50 kg. For persons weighing &lt; 50 kg, the following doses will be given: weight &gt; 25-32 kg - RPT 600 mg; weight &gt; 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max).</description>
    <arm_group_label>12-16 week rifamycin-based regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin and Isoniazid daily for 12 weeks</intervention_name>
    <description>Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)*.
*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.
RIF 600 mg daily for persons weighing &gt; 50 kg. For persons weighing &lt; 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max).</description>
    <arm_group_label>12-16 week rifamycin-based regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin daily for 16 weeks</intervention_name>
    <description>Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).*
*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.
RIF 600 mg daily for persons weighing &gt; 50 kg. For persons weighing &lt; 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg.</description>
    <arm_group_label>12-16 week rifamycin-based regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant, non-breastfeeding females &gt; 12 years old. Women of
             child-bearing potential who are not surgically sterilized must agree to practice an
             adequate method of contraception (barrier method or non-hormonal intrauterine device)
             or abstain from heterosexual intercourse during study drug treatment.

          -  Persons with LTBI who do not have evidence of TB disease and are at increased risk of
             progression to TB. M. tuberculosis infection may be demonstrated by either a positive
             tuberculin skin test (TST) or a positive interferon gamma release assay (IGRA; e.g.,
             QuantiFERON or T.SPOT.TB). Persons with LTBI at increased risk of progression to TB
             are those with one of the following:

               1. Household and other close contacts (&gt; 4 hours of exposure in a one week period)
                  within 2 years prior to enrollment, of persons with culture-confirmed TB A
                  positive nucleic acid amplification test (NAAT)/GeneXpert in the source case may
                  be used for enrollment prior to culture confirmation

               2. Recent M. tuberculosis infection, defined as converting from a documented
                  negative to positive TST or IGRA within 2 years prior to enrollment. Persons
                  without known close contact to someone with active pulmonary TB who have a
                  conversion by IGRA may require additional evaluation to rule out a false
                  conversion.

               3. HIV co-infection.

               4. â‰¥ 2 cm2 of pulmonary parenchymal fibrosis on chest X-ray and no prior history of
                  treatment for TB or LTBI.

               5. Recent (within 2 years prior to enrollment) immigration to the United States,
                  United Kingdom, or other country with low to moderate TB incidence, with abnormal
                  chest X-ray, and no evidence of active TB.

               6. Recent (within 2 years prior to enrollment) immigration to the United States,
                  United Kingdom, or other country with low to moderate TB incidence, from a
                  country with an estimated incidence rate of TB &gt; 150 per 100,000 (see Appendix
                  D).

               7. An increased risk of TB due to medical conditions such as end-stage renal
                  disease, or due to use of immunosuppressive medications such as chronic steroids
                  or TNF-alpha inhibitors.

          -  HIV-infected persons who are close contacts of a TB case, regardless of TST or IGRA
             result.

          -  Willing to provide signed informed consent, or parental permission and participant
             assent.

        Exclusion Criteria:

          -  Current confirmed culture-positive or clinical TB.

          -  Suspected current TB. Includes cases in which active TB cannot be eliminated as a
             possibility (by the site investigator)

          -  TB resistant to any rifamycin in the source case

          -  A history of treatment for &gt; 7 consecutive days with a rifamycin or &gt; 30 consecutive
             days with INH within 2 years prior to enrollment.

          -  A documented history of completing an adequate course of treatment for TB disease or
             LTBI in a person who is HIV-seronegative.

          -  History of allergy or intolerance to rifamycins.

          -  Serum alanine aminotransferase (ALT; SGPT) or serum aspartate aminotransferase (AST;
             SGOT) &gt; 5x upper limit of normal among persons in whom baseline ALT or AST is
             determined+.

          -  HIV-seropositive and on antiretroviral therapy that cannot be given with rifampin or
             rifapentine due to drug-drug interactions.

          -  Receiving concomitant medications that are known to be contraindicated with any study
             drug.

          -  Females who are currently pregnant, breastfeeding, or intend to become pregnant within
             120 days of enrollment.

          -  Weight &lt; 25 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Sterling, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt University Medical Center (USA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Belknap, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Denver Public Health (USA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim Abubakar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University College London, UK.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrey S Borisov, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centers for Disease Control (USA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrey S Borisov, MD, MPH</last_name>
    <phone>+1 (404)-639-8056</phone>
    <email>ABorisov@cdc.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>TBTC Research Administrator</last_name>
    <phone>+1 (800)-232-4636</phone>
    <email>tbtcresearchadmin@cdc.gov</email>
  </overall_contact_backup>
  <link>
    <url>https://www.cdc.gov/tb/topic/research/tbtc/default.htm</url>
    <description>Tuberculosis Trials Consortium (TBTC)</description>
  </link>
  <link>
    <url>https://www.cdc.gov/tb/topic/research/tbesc/default.htm</url>
    <description>Tuberculosis Epidemiologic Studies Consortium (TBESC)</description>
  </link>
  <link>
    <url>https://www.mrc.ac.uk/</url>
    <description>Medical Research Council (U.K.)</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>latent tuberculosis</keyword>
  <keyword>rifapentine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Rifamycin SV</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

